SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for its third fiscal quarter ended April 30, 2012. Revenue for the quarter was $207,000, compared with revenue of $128,000 for the same quarter of the prior year. The net loss for the quarter was $1.8 million, or $0.04 per share, compared with a net loss of $1.8 million, or $0.05 per share, in the third quarter last year.
